EGRX News and Press, Eagle Pharmaceuticals Inc. From 01/18/22

-- Shipment of vasopressin, a generic alternative to Vasostrict ® , commences today, with 180 days of marketing exclusivity -- -- Product launch expected to drive significant revenue growth in 2022 -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle...

-- Vasopressin shipments scheduled to commence January 17, 2022 -- -- Together with upcoming launch of PEMFEXY™ and advancements in pipeline, significant revenue growth expected this year -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the ...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40 th Annual J.P. Morgan Healthcare...

Eagle Pharmaceuticals (EGRX -0.2%) received 180 days of marketing exclusivity from the the U.S. Food and Drug Administration for its recently approved generic version of Endo International's (ENDP -1.5%) Vasostrict (vasopressin). Earlier in December, Eagle noted that that ...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new dru...

Eagle Pharmaceuticals (EGRX +2.2%) announces that Par Pharmaceutical has unilaterally withdrawn its bid to block the launch of the company’s recently approved generic alternative to Vasostrict through a court ruling. Par owned by Endo International (ENDP -2.2%) had earlier requested th...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restra...

In denying a Citizen Petition from Endo International (ENDP -12.4%) that sought to block approval of a generic of one of its drugs, the FDA says it is referring the company's attempt to the attention of the Federal Trade Commission. The petition "appears to have been submitted with the primar...

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 mil...

Eagle Pharmaceuticals (EGRX +13.1%) announced that the FDA has approved its abbreviated new drug application (“ANDA”) for vasopressin. The regulatory nod for the therapeutic equivalent of Vasostrict follows the recent legal battle won by Eagle (NASDAQ:EGRX) over Par Pharmaceutic...